Back to top
more

Regeneron Pharmaceuticals (REGN)

(Real Time Quote from BATS)

$830.39 USD

830.39
342,620

+13.74 (1.68%)

Updated Nov 7, 2024 12:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals

by Zacks Equity Research

This is the second pivotal late-stage study on SNY/REGN's Dupixent in chronic spontaneous urticaria indication to meet primary and key secondary endpoints.

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PBE

Bayer Reports Encouraging NSCLC Drug Data, Gets Approval for Eylea 8mg

by Zacks Equity Research

BAYRY's NSCLC drug BAY 2927088 shows an encouraging safety profile in the expansion part of the ongoing study. The company also announces the approval of Eylea 8mg.

GSK's Respiratory Drug Nucala Meets Goal in COPD Study

by Zacks Equity Research

GSK announces positive data from a phase III study of Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD).

Neena Mishra headshot

Why Biotech ETFs Are Beating the Market

by Neena Mishra

: Biotech stocks are poised to benefit from lower rates

Merck Starts Late-Stage Study on Recently Acquired Ophthalmology Drug

by Zacks Equity Research

The clinical study will evaluate MRK's experimental antibody treatment in patients with diabetic macular edema, a major cause of vision loss.

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PJP

Ekta Bagri headshot

Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More

by Ekta Bagri

Regeneron (REGN) and Lexicon (LXRX) are in the spotlight following drug approval and regulatory update, respectively.

Regeneron's Bispecific Antibody Obtains EC Nod for Lymphoma

by Zacks Equity Research

REGN's oncology portfolio gets a boost with the approval of odronextamab for treating follicular lymphoma and diffuse large B-cell lymphoma (DLBCL).

HRMY or REGN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HRMY vs. REGN: Which Stock Is the Better Value Option?

Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition

by Zacks Equity Research

Alnylam's (ALNY) Amvuttra and Givlaari sales continue to boost revenues. However, its reliance on collaboration partners and stiff competition remain concerns.

Ekta Bagri headshot

Biotech Stock Roundup: CRL for REGN, GILD's Drug Approval, LQDA Down on News

by Ekta Bagri

Bigwigs Regeneron (REGN) and Gilead Sciences (GILD) are in the spotlight following regulatory updates and drug approval, respectively.

Regeneron (REGN) Gets CRL From FDA for Multiple Myeloma Drug

by Zacks Equity Research

Regeneron (REGN) suffers a delay in obtaining FDA approval of linvoseltamab for the treatment of relapsed/refractory multiple myeloma.

Should You Invest in the VanEck Biotech ETF (BBH)?

by Zacks Equity Research

Sector ETF report for BBH

HRMY vs. REGN: Which Stock Is the Better Value Option?

by Zacks Equity Research

HRMY vs. REGN: Which Stock Is the Better Value Option?

Intellia's (NTLA) Q2 Earnings & Revenues Fall Shy of Estimates

by Zacks Equity Research

Intellia's (NTLA) second-quarter 2024 earnings and revenues lag estimates. The company provides developmental and regulatory updates on its pipeline candidates.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IBB

Bayer (BAYRY) Q2 Earnings In Line, Nubeqa, Kerendia Boost Sales

by Zacks Equity Research

Bayer's (BAYRY) second-quarter earnings match the consensus estimate. Sales gain from the Pharmaceutical business' strong performance.

Regeneron (REGN) Q2 Earnings Gain From Eylea HD, Dupixent

by Zacks Equity Research

Regeneron's (REGN) decent second-quarter results can be attributed to strong uptake of Eylea HD sales and high Dupixent profits, even though lead drug Eylea is under pressure.

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

by Zacks Equity Research

Sector ETF report for PJP

Alnylam (ALNY) Up as Q2 Earnings Beat on Collaboration Revenues

by Zacks Equity Research

Alnylam (ALNY) gains 13% on upbeat second-quarter results, beating both earnings and revenue estimates, primarily driven by higher collaboration revenues from Regeneron and strong Amvuttra sales.

Ultragenyx (RARE) Q2 Loss Narrower Than Expected, Revenues Up

by Zacks Equity Research

Ultragenyx (RARE) reports encouraging second-quarter 2024 results, beating both earnings and revenue estimates driven by the year-over-year increase of Crysvita and Dojolvi sales.

Ethan Feller headshot

Defensive Sectors Breakout: 3 Stocks to Buy Now for Protection

by Ethan Feller

AvalonBay Communities, Regeneron Pharmaceuticals and Public Service Enterprise Group are all rallying as investors rotate into defensive sectors

Compared to Estimates, Regeneron (REGN) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Regeneron (REGN) Tops on Q2 Earnings, Eylea HD, Dupixent Fuel Sales

by Zacks Equity Research

Regeneron (REGN) reports strong Q2 results, wherein both the top and bottom lines beat estimates due to higher Eylea HD and Libtayo sales and profits from Dupixent sales.